TORONTO, May 19, 2025, Deep Genomics, the AI-first TechBio organization pioneering a new path for genomic R&D, today announced the latest addition to its foundation model platform. The new deep learning model, REPRESS, accurately predicts microRNA (miRNA) binding and mRNA degradation directly from RNA sequences ...

Cambridge, MA/Toronto CA – April 14, 2025 – Deep Genomics, the AI-first TechBio organization pioneering a new path for genomic R&D with its AI foundation models platform, today announced two key executive hires joining the team amidst continued growth.  

• Monika Kowalczyk, MD, PhD, joins as Vice ...

Deep Genomics Awarded Stevies 2024 BioTechnology Company of the Year

Cambridge, MA– June 13, 2024 – Deep Genomics, the creator of BigRNA - the first AI foundation model for decoding RNA biology and designing therapeutics, today announced significant expansion milestones. The company celebrated the opening of its new office and lab facility in Cambridge, Massachusetts, the expansion ...

Company’s unique AI foundation model BigRNA is the first transformer neural network for the discovery of RNA biology and therapeutics

Represents a new generation of deep learning AI that can be applied to a range of different RNA therapeutic discovery tasks

Comprised of nearly ...

Remarks will highlight the latest deep learning technology from Deep Genomics for 

discovering RNA disease mechanisms and candidate therapeutics

TORONTO--(BUSINESS WIRE)--September 20, 2023 Deep Genomics, a leading AI drug development company focused on decoding biology to program life-changing medicines, announced today that its ...

O’Callaghan, a well-regarded life-science business leader with global experience and a significant track record of success, joins as part of plan to evolve Deep Genomics as a forward-integrated biopharmaceutical company 

Founder and current CEO Brendan Frey, Ph.D., F.R.S.C. to assume ...